These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 23676293

  • 1. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 2. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
    Lages B, Weiss HJ.
    Br J Haematol; 2001 Apr 15; 113(1):65-71. PubMed ID: 11328283
    [Abstract] [Full Text] [Related]

  • 3. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM, Buckland RJ, Holgate CE, Storey RF.
    Platelets; 2005 Nov 15; 16(7):398-407. PubMed ID: 16236601
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L, Alves VL, Phillips DR.
    Circulation; 2003 Mar 04; 107(8):1123-8. PubMed ID: 12615789
    [Abstract] [Full Text] [Related]

  • 5. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
    Goto S, Tamura N, Li M, Handa M, Ikeda Y, Handa S, Ruggeri ZM.
    J Thromb Haemost; 2003 Sep 04; 1(9):2022-30. PubMed ID: 12941046
    [Abstract] [Full Text] [Related]

  • 6. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S, Lassila R.
    Thromb Res; 2006 Sep 04; 117(3):291-7. PubMed ID: 15878612
    [Abstract] [Full Text] [Related]

  • 7. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
    Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK.
    J Thromb Haemost; 2009 Jun 04; 7(6):983-91. PubMed ID: 19548907
    [Abstract] [Full Text] [Related]

  • 8. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 04; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 9. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 04; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 10. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Jun 04; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 11. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G.
    J Thromb Thrombolysis; 2001 Apr 04; 11(2):99-110. PubMed ID: 11406724
    [Abstract] [Full Text] [Related]

  • 12. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR, Malik IS, Weerasinghe A, Poullis M, Nadra I, Haskard DO, Taylor KM, Landis RC.
    Heart; 2004 Jul 04; 90(7):794-9. PubMed ID: 15201252
    [Abstract] [Full Text] [Related]

  • 13. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 04; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 04; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 15. In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats.
    Magee AN, Hogan DF, Sederquist KA, Durham JA.
    Am J Vet Res; 2014 Mar 04; 75(3):309-12. PubMed ID: 24564318
    [Abstract] [Full Text] [Related]

  • 16. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 17. Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
    Weber AA, Meila D, Jacobs C, Weber S, Kelm M, Strauer BE, Zotz RB, Scharf RE, Schrör K.
    Thromb Res; 2002 Apr 01; 106(1):25-9. PubMed ID: 12165285
    [Abstract] [Full Text] [Related]

  • 18. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
    Speich HE, Furman RR, Lands LT, Moodie GD, Jennings LK.
    J Thromb Thrombolysis; 2013 Jul 01; 36(1):31-41. PubMed ID: 23073747
    [Abstract] [Full Text] [Related]

  • 19. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
    Schrör K.
    Herz; 2001 Apr 01; 26 Suppl 1():30-5. PubMed ID: 11349624
    [Abstract] [Full Text] [Related]

  • 20. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
    Matsumoto Y, Marukawa K, Okumura H, Adachi T, Tani T, Kimura Y.
    Thromb Res; 1999 Jul 01; 95(1):19-29. PubMed ID: 10403683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.